English

Increased number of shares entered into trade register

Report this content

Revenio Group Corporation, Stock Exchange Release, May 9, 2019 at 9:00

INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

Total of 6,270 new share subscriptions based on the company's 2015A stock options approved by the Board of Directors of Revenio Group Corporation on April 29, 2019, have been entered into the trade register today. The share subscription price under 2015A option rights was 7.95 EUR per share. The subscription period for 2015A options is May 31, 2017 – May 31, 2019.

After these subscriptions, the number of Revenio Group Corporation's shares and votes will rise to 26,372,746. The subscription price of the shares is recorded in their entirety in the reserve for invested unrestricted equity.

Revenio Group Corporation has applied for the listing of its new shares on the Nasdaq Helsinki in the same series as the company's existing shares. According to the current estimate, the new shares will be listed on May 10, 2019.

Revenio Group Corporation
Board of Directors

For further information, please contact:
Timo Hildén, CEO, tel.  +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media

www.revenio.fi 

Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on strongly patented intraocular pressure measurement technology.

The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. Revenio’s core business is to develop and commercialize effective and easily adopted devices to assist in the diagnostics of glaucoma and its monitoring during treatment.

Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's technology is on the early detection of glaucoma, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2018, Revenio Group's net sales totalled EUR 30.7 million, with its net operating profit standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.